PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11164833-3	2001	injection of racemic-flurbiprofen (0.3, 3 and 9 mg/kg) has weaker effects on carrageenan-evoked spinal c-Fos protein expression and peripheral edema than those previously described in the same inflammatory nociceptive model in awake rats.	Flurbiprofen	21-33	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	103-108	
9776348-7	1998	Intravenous racemic-flurbiprofen (0.3, 3 and 9 mg kg(-1)) dose-relatedly reduced the carrageenan-evoked oedema and spinal c-Fos expression (r=0.64, r=0.88 and r=0.84 for paw diameter, ankle diameter and number of c-Fos-LI neurons; P&lt;0.05.	Flurbiprofen	20-32	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	122-127	
11011034-0	2000	Effects of flurbiprofen and its enantiomers on the spinal c-Fos protein expression induced by noxious heat stimuli in the anaesthetized rat.	Flurbiprofen	11-23	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	58-63	
11011034-4	2000	The same doses of R(-)-flurbiprofen produced dose-related effects (r=0.58, P&lt;0.05) with weak, but significant, effects for doses of 3 and 9 mg/kg (18+/-6% and 26+/-5% reduction of the number of noxious heat-evoked c-Fos-IR nuclei in laminae I-II, P&lt;0.05 and P&lt;0.01, respectively).	Flurbiprofen	18-35	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	217-222	
9776348-7	1998	Intravenous racemic-flurbiprofen (0.3, 3 and 9 mg kg(-1)) dose-relatedly reduced the carrageenan-evoked oedema and spinal c-Fos expression (r=0.64, r=0.88 and r=0.84 for paw diameter, ankle diameter and number of c-Fos-LI neurons; P&lt;0.05.	Flurbiprofen	20-32	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	213-218	
9776348-10	1998	Similar effects to those of intravenous racemic-flurbiprofen were obtained with intravenous S(+)-flurbiprofen (0.3, 3 and 9 mg kg(-1)) which dose-relatedly reduced the number of c-Fos-LI neurons (r=0.69, P&lt;0.01) and diameters of paw and ankle (r=0.56 and r=0.52 respectively, P&lt;0.05 for both).	Flurbiprofen	92-109	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	178-183	
9776348-16	1998	Intraplantar racemic-flurbiprofen (1, 10 and 30 microg) dose-relatedly reduced the carrageenan-enhanced ankle diameter (r=0.81, P&lt;0.001) and the number of c-Fos-LI neurons in L4-L5 segments (r=0.83, P&lt;0.001).	Flurbiprofen	21-33	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	158-163	
9776348-19	1998	For intraplantar S(+)-flurbiprofen (1, 10 and 30 microg) the dose-related effects (r=0.77, r=0.60 and r=0.59 for c-Fos-LI neurons, paw and ankle diameters respectively, P&lt;0.001, P&lt;0.01 and P&lt;0.01) were similar to those of racemic-flurbiprofen.	Flurbiprofen	18-34	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	113-118	
9776348-19	1998	For intraplantar S(+)-flurbiprofen (1, 10 and 30 microg) the dose-related effects (r=0.77, r=0.60 and r=0.59 for c-Fos-LI neurons, paw and ankle diameters respectively, P&lt;0.001, P&lt;0.01 and P&lt;0.01) were similar to those of racemic-flurbiprofen.	Flurbiprofen	22-34	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	113-118